---
layout: default
title: Abatacept
parent: 僅模型預測 (L5)
nav_order: 13
evidence_level: L5
indication_count: 10
---

# Abatacept
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# ABATACEPT: Drug Repurposing Evaluation Report

## One-Sentence Summary

Abatacept (DrugBank: DB01281) is a biologic known internationally for immunomodulatory applications.
The TxGNN model has **not yet generated predicted new indications** for this drug,
and it is currently **not marketed in Taiwan** with **0 authorizations** on record.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not available in current dataset |
| Predicted New Indication | None (no TxGNN predictions available) |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — Model prediction not yet available |
| Taiwan Market Status | ✗ Not marketed (未上市) |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the evidence pack. Abatacept (DB01281) is registered in the DrugBank database, but the original MOA field and original indication list have not yet been populated in this dataset.

Without a TxGNN-predicted indication, a mechanistic plausibility analysis cannot be performed at this time. The absence of a prediction does not necessarily mean the drug lacks repurposing potential — it may indicate that the drug-disease knowledge graph edges have not yet been fully processed, or that the model's confidence for candidate indications fell below the reporting threshold.

To advance this candidate, the MOA data gap (DG002) must first be resolved by querying the DrugBank API, and the TxGNN prediction pipeline should be re-run once the knowledge graph inputs are complete.

---

## Clinical Trial Evidence

Currently no TxGNN-predicted indication is available, therefore no targeted clinical trial search has been conducted.

---

## Literature Evidence

Currently no TxGNN-predicted indication is available, therefore no targeted literature search has been conducted.

---

## Taiwan Market Information

Abatacept currently holds **no TFDA authorizations** and is **not marketed in Taiwan**. No license records are available.

---

## Safety Considerations

> Please refer to the package insert for safety information. Key warnings, contraindications, and drug interaction data are not yet available in this evidence pack. Resolution of data gap DG001 (TFDA package insert warnings/contraindications) is classified as **Blocking** severity and must be addressed before Stage 1 safety screening can proceed.

---

## Data Gaps Summary

The following critical data gaps were identified during evidence pack assembly:

| Gap ID | Item | Severity | Impact | Remediation |
|--------|------|----------|--------|-------------|
| DG001 | TFDA Package Insert Warnings/Contraindications | **Blocking** | Cannot enter S1 safety screening | Download and parse package insert PDF from TFDA website |
| DG002 | Mechanism of Action (MOA) | **High** | Affects mechanistic relevance analysis | Query DrugBank API |

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
No TxGNN-predicted indications are currently available for Abatacept, and two significant data gaps (MOA and TFDA safety data) remain unresolved. The Blocking-severity gap (DG001) prevents entry into Stage 1 safety assessment.

**To proceed, the following is needed:**
- **Resolve DG001 (Blocking):** Obtain and parse the TFDA package insert to extract warnings, contraindications, and safety information
- **Resolve DG002 (High):** Query the DrugBank API to retrieve the detailed mechanism of action
- **Re-run TxGNN prediction pipeline** once knowledge graph inputs for Abatacept are complete
- **Re-query clinical trials and literature databases** once a predicted indication is available
- **Reassess Taiwan regulatory pathway** if a viable repurposing candidate emerges, given that Abatacept is currently not marketed in Taiwan
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

